Mutation Variants and Co‐Mutations as Genomic Modifiers of Response to Afatinib in HER2‐Mutant Lung Adenocarcinoma

BACKGROUND: Human epidermal growth factor receptor 2 (HER2)‐mutant lung cancer remains an orphan of specific targeted therapy. The variable responses to anti‐HER2 therapies in these patients prompt us to examine impact of HER2 variants and co‐mutations on responses to anti‐HER2 treatments in lung ca...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Fang, Wenfeng, Zhao, Shen, Liang, Ying, Yang, Yunpeng, Yang, Lin, Dong, Xiaorong, Zhang, Li, Tang, Yong, Wang, Shoufeng, Yang, Yang, Ma, Xiaoyan, Wang, Minghui, Wang, Wenjing, Zhao, Songhui, Wang, Kai, Gao, Song
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley & Sons, Inc. 2019
Assuntos:
Lung Cancer
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066719/
https://ncbi.nlm.nih.gov/pubmed/32162827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0547
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares